gene in patients relapsing just after treatment method While using the BCL2 antagonist venetoclax. sixty six Resistance to these agents has been connected with these mutations in around 70% of cases, Though they are usually subclonal as well as their certain purpose triggering resistance must be demonstrated.Not all clients with CLL demand therapy.